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Abstract.
Background: Four previously reported studies have tested for association of blood proteins with neocortical amyloid- burden
(NAB). If shown to be robust, these proteins could have utility as a blood test for enrichment in clinical trials of Alzheimer’s
disease (AD) therapeutics.
Objective: This study aimed to investigate whether previously identified blood proteins also show evidence for association with
NAB in serum samples from the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL). The study
considers candidate proteins seen in cohorts other than AIBL and candidates previously discovered in the AIBL cohort.
Methods: Our study used the SOMAscan platform for protein quantification in blood serum. Linear and logistic regressions
were used to model continuous NAB and dichotomized NAB respectively using single proteins as a predictor. Multiple protein
models were built using stepwise regression techniques and support vectors machines. Age and APOE 4 carriage were used as
covariates for all analysis.
Results: Of the 41 proteins previously reported, 15 AIBL candidates and 20 non-AIBL candidates were available for testing. Of
these candidates, pancreatic polypeptide (PPY) and IgM showed a significant association with NAB. Notably, IgM was found
to associate with continuous NAB across cognitively normal control subjects.
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Conclusions: We have further demonstrated the association of PPY and IgM with NAB, despite technical differences between
studies. There are several reasons for a lack of significance for the other candidates including platform differences and the use
of serum rather than plasma samples. To investigate the possibility of technical differences causing lack of replication, further
studies are required.
Keywords: Alzheimer’s disease, amyloid plaques, blood, positron emission tomography scan, proteomics
INTRODUCTION
The pathology of AD is characterized by three fea-
tures in the brain: the aggregation of amyloid- (A)
into plaques, the presence of hyperphosphorylated tau
in the form of tangles, and the occurrence of neuron
loss leading to brain atrophy [1, 2]. There is debate
as to how these processes interact to cause symp-
tomatic AD. A popular theory is the amyloid cascade
hypothesis: that A deposition is central to disease
development [3]. Studies show that A plaques begin
to develop up to 20 years prior to clinical diagnosis
with their growth reaching a plateau as clinical symp-
toms arise [4, 5]. The presence of AD pathology can be
investigated through characteristics that are informa-
tive of AD diagnosis; endophenotypes. Measurements
of analytes in cerebrospinal fluid (CSF) and molecular
imaging by positron emission tomography (PET) scans
are examples of endophenotypes that are biomarkers
for AD. The disadvantages of the procedures involved
in attaining these measurements include their invasive
or expensive nature and that they require specialized
administration.
Existing treatments for AD provide short-term
symptomatic relief, in a subset of patients, and trials
of potential disease modifying treatments are failing
[6]. Two suggestions have been made to address this
shortcoming: the use of A as a companion diag-
nostic in tertiary prevention trials (those investigating
disease modifying or symptomatic treatments) and in
secondary prevention trials (investigating treatments to
prevent the disease from occurring in the first place).
Firstly, we consider the use of a companion diagnos-
tic in a normal clinical trial. To date, trials of A
targeting drugs have recruited patients with a clini-
cal AD or mild cognitive impairment (MCI) diagnosis
and unknown brain A burden [7–10]. As A PET
scans became more readily available, toward the end
of such trials, A burden was measured and it was dis-
covered that some of these AD patients had low A
burden (the target pathology). For example, in a trial
of Bapineuzumab, a humanized anti-A monoclonal
antibody, approximately 14% of subjects had low A
burden [9]. Consequently, it has been suggested that
A PET or CSF measures are used as a companion
diagnostic, with elevated brain A becoming an eligi-
bility requirement for A-lowering trials. A panel of
blood biomarkers could enable cost-effective enrich-
ment and identification of trial participants with A
pathology for subsequent confirmatory A CSF tests
or PET scans.
A second use of a blood-based biomarker would
be in recruitment for secondary prevention trials. It is
hypothesized that the brains of people recruited with
a diagnosis of AD or MCI are often too damaged for
medication to have an effect. Treatments could have
a higher chance of success in subjects with no clini-
cal symptoms, under the assumption that it is easier
to delay, rather than reverse, the development of AD
pathology. Aisen et al. expand on this idea stating that
there has been no medical advancements in the last
decade in terms of treating AD [11]. They suggest bas-
ing recruitment of patients into clinical trials on the
presence of biomarker defined pre-symptomatic AD;
three such trials had begun by the end of 2014. As
above, using a blood biomarker as an enrichment filter
for PET scans and CSF markers could increase the effi-
ciency of clinical trial recruitment by reducing screen
failures. A simple blood test has the greatest potential
impact in streamlining secondary prevention studies as
screen failure rates due to low A are expected to be
higher (∼78.1% versus ∼12%) in asymptomatic indi-
viduals than in subjects with AD (Ossenkoppele et al.
and Jansen et al., unpublished results).
Consequently, there is high demand for a blood-
based biomarker of AD pathology [12]. It has been
shown that measures of A in the brain are highly neg-
atively correlated with those in the CSF [13]. However,
overall, studies of blood A do not show similar cor-
relations [14]. It is therefore necessary to search for
other analytes within the blood that may be associated
with A in the brain. Recent studies provide some evi-
dence that proteins in blood show such a link to other
AD endophenotypes and to A burden in the brain
[15–19]. However, there is a need to investigate these
results further in independent datasets of a larger size,
using different technologies and different biological
samples. We begin to address this here.
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This study aimed to further test findings in the litera-
ture of proteins in blood plasma associating with brain
A burden [15–17, 19]. We used a radioactive marker
of A, [11C]-Pittsburgh compound B (PiB), combined
with PET scanning to quantify the amount of brain A
burden and the SOMAscan proteomics platform [20]
for quantification of protein in blood samples.
With over 1,000 protein analytes, the SOMAscan
proteomics platform has been used in high-throughput
biomarker discovery studies. For example, in AD
research it has been used by Sattlecker et al. and
Zhao et al. to discover potential plasma biomarkers
of AD diagnosis, MRI measures, and/or rate of cog-
nitive decline [18, 21]. In this study we focused our
approach on candidate-based analysis, selecting only
proteins previously found to associate with NAB. This
was done to ensure that there was sufficient statisti-
cal power to detect weaker signal that could have been
missed had the entire SOMAscan panel been used. This
analysis was repeated within just the cognitively nor-
mal control subjects to evaluate whether this test would
have utility to enrich for A-positivity in secondary
prevention trials.
MATERIALS AND METHODS
Cohort
AIBL is a prospective, longitudinal study of sub-
jects aged over 60 years. The dual center study recruits
subjects with an AD diagnosis as well as both control
subjects and those with MCI with the aim of identify-
ing factors that lead to subsequent AD development.
Details of study design and enrolment are given else-
where [17]. The present study comprised a subset of
198 subjects from AIBL, enriched for controls.
Proteomics
Blood draws (80 ml) were taken after overnight fast-
ing and serum was collected in Sarsedt s-monovette
tubes. The samples were centrifuged at 1,800 g for
15 min at 20◦C and immediately frozen at −80◦C.
They were stored (long-term) in liquid nitrogen [22].
Protein levels in the blood serum were analyzed using
the SOMAscan platform (SomaLogic Inc, Boulder,
CA). The methods used in this assay are outlined
in detail by Kraemer et al. but, in brief, proteins
were measured using Slow Off-rate Modified Aptamer
(SOMAmer)-based capture arrays using a sample
of less than 10L per run [23]. SOMAmers are
nucleotides that have been chemically modified to
address two issues: hard to capture proteins and non-
specific binding. Firstly, the nucleotides are given
protein-like properties resulting in high affinity for
hard to capture proteins. Secondly, aptamers with
slow dissociation rates are used allowing disruption
of non-specific binding. These nucleotides are used to
transform a protein signal to a nucleotide signal that
can be quantified using relative florescence on microar-
rays. For full quantification details of this assay, see
Gold et al. [20]. This study used SOMAscan Version
2 which captured information on 1,001 proteins and
protein complexes.
Quality control was performed at the sample and
SOMAmer level, and involved the use of control
SOMAmers on the microarray and calibration samples.
Hybridization controls measured sample-by-sample
variation in hybridization while the median signal over
all SOMAmers measured technical variability. Scale
factors of these two metrics were used to normalize
across all samples with acceptance criteria of 0.4 to
2.5 based on historic trends. SOMAmer by SOMAmer
calibration occurred through the repeated measure-
ment of calibration samples. Historic values were
used to generate a calibration scale factor the accep-
tance criterion for which was: 95% of SOMAmers
must have a calibration scale factor within 0.4 of the
median.
Imaging
The measures of NAB used in this study were
collected by PiB PET scans. The PiB imaging method-
ology is detailed elsewhere [24]. Each scan was
spatially normalized by Rowe et al. to a customized
PiB-PET template in the Montreal Neurological
Institute reference space using Statistical Parametric
Mapping 8 (SPM8; Wellcome Trust Centre for Neu-
roimaging, London, UK). Standardized uptake value
ratios (SUVRs) were then created by computing the
ratio of PiB retention in the whole brain to that in the
grey matter [25].
Identiﬁcation of candidate blood protein markers
of brain Aβ burden
We identified candidate proteins through a search
of the literature for studies investigating the relation-
ship between blood proteomics and A burden in the
brain. Any proteins identified as significant in the study
conclusions were selected and matched to the AIBL
SOMAscan data using the UniProt ID.
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Statistical analysis
All statistical analysis was performed in R (version
3.1.1) [26].
Differences in proteomic signal between platforms
and sample types
As the candidates were selected based on their asso-
ciation with NAB in plasma, we aimed to confirm
that serum is an appropriate surrogate by compar-
ing proteomic signal from the SOMAscan platform
between blood plasma and serum samples using age
as an outcome. We also studied differences between
the SOMAscan platform and Myriad’s Rules Based
415 Medicine Multi-analytes Profile (RBM MAP),
one of the discovery proteomics platforms. To do so,
we used proteomic data generated using the RBM
MAP platform from the original publication of a blood
biomarker in the AIBL study; methods described by
Burnham et al. [17].
Menni et al. have studied associations of age with
protein levels from plasma samples using the TwinsUK
cohort and SOMAscan version 3 [27]. Running ran-
dom intercept linear regression, adjusting for family
relatedness, identified proteins associated with chrono-
logical age. We performed a similar analysis using
standard linear regression on our serum samples from
the AIBL cohort. Within each cohort (TwinsUK and
AIBL) the proteins were ranked by p-value from the
regressions and the R package OrderedList was used to
compare the rank of proteins present on both versions
of the platform [28].
To assess the concordance of proteomic signal
between SOMAscan and RBM MAP, we implemented
an identical method. OrderedList was used to compare
lists of proteins ranked according to their associations
with age and gender.
Analysis overview
An overview of the analysis is given in Fig. 1.
Proteins discovered in studies other than AIBL
[15, 16] were analyzed separately to proteins discov-
ered in AIBL using different biological samples (serum
instead of plasma) [17, 19]. This split was implemented
as the association of a non-AIBL candidate with NAB
in AIBL would provide a fully independent replica-
tion of those findings, whereas the association of an
AIBL candidate with NAB would only show that the
marker could also be measured using SOMAmers on
serum samples. Each analysis tested the protein levels
against the continuous endpoint of SUVR as well as a
dichotomized high/low NAB endpoint. A cut off of 1.3
was used to distinguish between high and low NAB
[17]. Use of a continuous endpoint gives increased
power in statistical analysis in comparison to a categor-
ical measure [29]. Additionally, each analysis studied
all samples and control samples alone.
Subjects were randomly split into a training (66%)
and test set (34%) using the createDataPartition func-
tion in the R package caret [30]. The split ensured that
a range of values of NAB were present in each set for
the continuous analysis by splitting the subjects into
groups based on NAB percentiles and sampling within
these groups. For the dichotomized analysis, the split
ensured that the proportion of high and low NAB was
similar between the two sets by sampling within the
high and low groups.
Data pre-processing
Data pre-processing was performed separately for
each analysis. In both cases, all protein data was subject
to a natural logarithm transformation so each protein
followed an approximate normal distribution. Per sam-
ple, per protein outliers were then identified as values
lying outside of 6 standard deviations (SD) of the mean
protein value and were set to missing. Any sample with
more than 20% missing data was removed. Missing
data in the train and test sets was imputed separately
using 10 nearest neighbors.
In some cases, there were multiple SOMAscan
probes available for one UniProt ID. In this instance, a
principal components analysis (PCA) was performed
across these probes and only the first principal com-
ponent (PC1) was included in the analysis. This was
performed on all samples and on control samples alone,
and separately for train and test sets. Additionally, the
colinearity of such probe sets was investigated using
Pearson’s correlation coefficients.
Single protein analysis
Models were built using the training set. The contin-
uous and dichotomized NAB endpoints were regressed
against age, APOE 4 load and each protein in turn
using linear and logistic regression, respectively. Age
and APOE 4 load, defined as the number of 4 alle-
les in a subjects genotype, were included as they were
statistically significant in this population (see Table 2).
In all cases, Benjamini Hochberg corrected p-values
from the full model fit (q-values) were tested against
a significance level of 0.1, to account for false discov-
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Fig. 1. Overview of data analysis.
ery. Although the hypothesis tests performed were not
independent, the Benjamini Hochberg correction gave
an acceptable approximation of the false discovery rate
[31].
Model fit was assessed by exploring the residuals of
each model to ensure normality, constant variance, zero
expectation, and independence. For logistic regression
models, deviance residuals were used.
Each model was used to predict NAB in the test set
and model statistics were calculated. These were R2
and root mean squared error (RMSE) for linear regres-
sion and accuracy, sensitivity and specificity for logistic
regression.Foreachmodel,statisticpermutationtesting
was run with 1,000 permutations of the NAB values,
to create a non-parametric, empirical p-value. In each
permutation, the relationship between NAB endpoint,
age, and APOE 4 load was maintained. Benjamini
Hochberg corrected p-values (q-values) were tested
against a significance level of 0.1.
Multiple protein analysis
The primary multiple protein analysis was paramet-
ric. Models were built using the training set. As in the
single protein analysis, continuous and dichotomized
NAB endpoints were regressed against age, APOE 4
load, and all proteins together (15 non-AIBL candi-
dates and 20 AIBL candidates) using linear and logistic
regression respectively. The models were then sim-
plified using stepwise regression based on Akaike’s
Information Criteria (AIC). Simplified linear regres-
sion models were examined for variable importance
using the Lindemann, Merenda, and Gold (LMG) mea-
sure [32]. This metric represents the R2 of an individual
regressor by averaging over all orders of regressors.
Each model was used to predict on the test set and cre-
ate model statistics with associated empirical p-values,
as detailed previously. Model fit was assessed in the
same manner as for the single protein analysis.
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As a secondary multiple protein analysis we inves-
tigated the possibility of non-linear associations and
interactions by performing a non-parametric multiple
protein analysis using support vector machines (SVMs)
in the R package kernlab [33]. We used an SVM with
radialkernel tobuildmodels in the trainingset.The train
function from the R package caret was used to estimate
model parameters: The kernel parameter (sigma) was
directlyestimatedandregularizationparameter (C)was
tuned using 25 bootstraps. RMSE was used as the opti-
mization metric for continuous NAB while kappa was
used for the dichotomized endpoint. Each model was
used to predict on the test set.
RESULTS
Cohort demographics
For this study, we used SOMAscan data generated
on serum samples from the AIBL cohort. Table 2
summarizes the demographics of this population. As
expected, characteristic features of AD such as Mini-
Mental State Examination score and Clinical Dementia
Rating were significantly associated with continuous
NAB and significantly different between high and low
NAB groups. Age and APOE 4 load (defined as the
number of APOE 4 alleles in a subject’s genotype)
were also significant and hence accounted for in all
analyses.
Overall, demographics in the control population
mirrored those across all samples and hence the same
terms were covaried for in the control only analyses
(see Supplementary Table 1). As expected, measures
of APOE4 were not significant in this sub-population.
Differences in proteomic signal between platforms
and sample types
We began by comparing proteomic signal associated
with age in plasma samples from the TwinsUK cohort
and serum samples from AIBL. 975 SOMAscan probes
matched between the Twins UK (Version 3, 1,129
SOMAmers) and AIBL (Version 2, 1,001 SOMAmers)
datasets mapped using SOMAscan ID. Comparison of
the protein lists ranked by association with age gave a
significance of similarity p-value of <0.001. The anal-
yses were not adjusted for any covariates.
We also made a comparison between the SOMAscan
platform and RBM MAP platform using samples from
the AIBL cohort. The RBM MAP data contained 151
proteins, 119 of which could be mapped to a UniProt
ID. All 1,001 proteins on the SOMAscan panel were
mapped to a UniProt ID. There were 88 proteins
that overlapped between the two datasets, mapped by
UniProt ID. Comparison of the protein lists ranked by
association with age gave a significance of similarity
p-value of 0.162. An identical analysis with proteins
ranked by association with gender gave a significance
of similarity p-value of 0.201.
Identiﬁcation of candidate blood protein markers
of brain Aβ burden
We identified four previous studies investigating a
proteomic signal in the blood associated with A bur-
den in the brain. Previously reported studies used blood
plasma whereas this study uses blood serum samples.
Thambisetty et al. discovered six proteins associated
with brain A burden in a group of non-demented,
older individuals [15]. Kiddle et al. used data from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
in a discovery analysis to find 16 proteins associated
with brain A burden [16]. Significant proteins from
these two papers that were also present in the AIBL
SOMAscan data [15] are termed non-AIBL candidates
and are given in Table 1.
Additionally, two discovery analyses have already
been performed on AIBL subjects using different pro-
tein measurement technologies; RBM MAP [17] and
mass spectrometry [19]. Respectively, these studies
highlighted 8 and 17 proteins (a prioritized set) as being
significantly associated with NAB. The proteins that
were also present in the AIBL SOMAscan data [20]
are termed AIBL candidates and are given in Table 1.
See Supplementary Figure 1 for an overview of protein
numbers.
In some cases, there were multiple SOMAscan
aptamers for one UniProt ID: C3 (P01024) had six
matches in the AIBL SOMAscan dataset, APOE
(P02649) had three, and Fibrinogen ([P02671, P02675,
P02679]) had two. All are accounted for in this anal-
ysis using PCA as detailed previously. Eleven of the
41 proteins were not present on the SOMAscan panel.
APP was included as an additional protein of interest
as A1–42 is not present on the SOMAscan panel.
Data pre-processing
There was no observed pattern in the missing data
nor in the demographics of the subjects with data set
to missing so it was assumed the data were missing at
random. No subjects were removed during data pre-
processing.
The protein data was generated in one batch and
the PET scans were performed using one model of
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Table 2
Population demographics
Total Overall High NAB Low NAB High/Low
n = 198 p-value n = 107 n = 91 p-value
Gender (% female) 50 0.96 49 52 0.78
APOE status (% of APOE 4 positive) 51 <0.001 61 50 0.004
APOE 4 load (% with loads 0; 1; 2) 49; 43; 8.1 <0.001 39; 48; 13 60; 37; 2.2 0.002
Median age [IQR] (years) 72 [14] <0.001 76 [11] 68 [12] <0.001
Median MMSE score [IQR] 28 [3.0] <0.001 28 [4.0] 29 [2.0] <0.001
Global CDR status (%>0) 44 <0.001 64 21 <0.001
Clinical diagnosis (% with diagnosis 14; 26; 61 0.28 25; 35; 40 0; 15; 85 <0.001
AD; MCI; Control)
Individuals were positive for APOE 4 if at least one APOE 4 allele was seen in their genotype.
APOE 4 load was the number of 4 alleles seen in a subject’s genotype.
IQR, inter-quartile range; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating.
Overall p-value: Result of the Kendall tau test for dependence between SUVR and the demographics variable.
High/low p-value: Kruskal Wallis Chi-Squared was used to test between high and low groups for continuous data.
High/low p-value: Fishers exact was used to test between high and low groups for categorical data.
Table 3
Candidate proteins of the same UniProt ID
UniProt ID Proteins Minimum-Maximum
Correlation
P01024 C3; C3adesArg; C3b; 0.468 – 0.964
iC3b; C3a; C3d
P02671 Fibrinogen; D-dimer 0.651
P02649 APOE; APOE3; APOE4 0.787 – 0.894
machine. Table 3 gives details of the proteins that
were collapsed into their first principal component, as
detailed previously. In all cases, PC1 accounted for at
least 75% of the total variation. The only probe leading
to correlations of less than 0.75 for UniProt ID P01024
was that of C3d.
Discovery analysis
Discovery analysis was applied across the entire
SOMAscan platform in an attempt to find predic-
tors of dichotomized as well as continuous NAB.
Variable selection techniques that included linear and
logistic regression and SVMs yielded no predictive
models with efficacy of estimating NAB above that
of a model built on age and APOE 4 carriage alone.
The results of linear and logistic regression methods to
predict continuous and dichotomized NAB are given in
Supplementary Table 2.
Single protein analysis
Residual plots indicated a reasonable model fit in
all cases. We outline below single proteins that pass
multiple testing with a q-value of less than 0.1.
Fig. 2. Regression fit for PPY modeling dichotomized NAB in all
samples: training data.
Non-AIBL candidates
When modeling dichotomized NAB, logistic regres-
sion analysis showed that PPY was significantly
associated with PiB positivity across all samples, pass-
ing multiple testing corrections (= 2.959, p = 0.001,
q = 0.013). Figure. 2 shows the fit of this model in
the training data. See Supplementary Table 3 for full
results.
AIBL candidates
In control samples, IgM was significant in a linear
model with a q-value of 0.044 (= −0.282, p = 0.002).
Mirroring the non-AIBL candidate results, PPY
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Fig. 3. Regression fit for IgM modeling continuous NAB in control
samples: training data.
was significant in a logistic regression model when
considering the dichotomized endpoint in all samples
(q = 0.018). Figures 2 and 3 show the fit of these mod-
els in the training data. See Supplementary Table 4 for
full results.
The analysis of continuous NAB against IgM in con-
trol subjects was repeated including a flag for presence
of diabetes as a covariate (n = 72). IgM had an esti-
mate similar to that previously stated (= −0.232) and
showed a nominally significant p-value (p = 0.027).
The presence of diabetes flag was not significant
(= 0.127, p = 0.586).
Multiple protein analysis
Continuous NAB
In linear regression analysis across all subjects mod-
els of both non-AIBL candidates and AIBL candidates
showed improved RMSE (0.490 and 0.497) and R2
(0.245 and 0.226) values over a model of age and
APOE alone (RMSE = 0.500 and R2 = 0.219). The
model of non-AIBL candidates achieved significant
empirical p-values for RMSE and R2 through per-
mutation testing with p-values of 0.041 and 0.043,
respectively. Model statistics achieved in parametric
analysis outperformed those from SVM modeling.
Table 5
Multiple protein analysis: continuous NAB
Population Candidates Method Test data
R2 R2 RMSE RMSE
Empirical Empirical
p-value p-value
All Non-AIBL Linear regression 0.245 0.043 0.49 0.041
[Age, APOE 4 number,
Albumin PPY]
SVM 0.15 – 0.52 –
AIBL Linear regression 0.226 0.061 0.497 0.058
[Age, APOE 4
number, BLC, C4]
SVM 0.15 – 0.53 –
Age and APOE Linear regression 0.219 – 0.5 –
[Age and APOE 4 number]
SVM 0.1 – 0.53 –
Controls Non-AIBL Linear regression 0.241 0.215 0.356 0.226
[Age, APOE 4 number,
vWF, PPY, Plasmingen]
SVM 0.23 – 0.36 –
AIBL Linear regression 0.17 0.371 0.392 0.537
[Age, APOE 4 number,
IgM, BLC, Alpha-2-Macroglobulin,
HRG, Factor B, Hemopexin]
SVM 0.25 – 0.36 –
Age and APOE Linear regression 0.273 – 0.349 –
[Age and APOE 4 number]
SVM 0.02 – 0.41 –
PC1, First Principal Component;
SVM, Support Vector Machine.
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Protein models in control samples created through
regression analysis did not outperform a model of
age and APOE alone. However, all SVM models
showed lower RMSE and higher R2 values than the
demographic only model and in most cases also
outperformed the parametric methods. For further
details of the multiple protein analysis of continuous
NAB, see Table 5.
Dichotomized NAB
In parametric analysis across all subjects, the model
of AIBL candidates gave a higher accuracy (0.612)
than a model of age and APOE alone (0.567). This
was driven by an increase in specificity; 0.583 com-
pared with 0.389 in the age and APOE only model.
Specificity gave a significant permutation p-value of
0.026.
The model of non-AIBL candidates also showed
increased specificity at 0.444 compared to 0.389 in
the age and APOE only model. SVM analysis gave
increased specificity and decreased sensitivity over
parametric analysis in all three models leading to a
marginal increase in overall accuracy.
In control samples, logistic regression analysis of
AIBL candidates gave improved accuracy and sensi-
tivity compared with the model of age and APOE alone
(0.675 and 0.444, respectively, compared with 0.650
and 0.333). The model in non-AIBL candidates also
showed increased sensitivity at 0.500. Non-parametric
analysis showed improved accuracy over regression
analysis in the protein based models driven by an
increase in sensitivity. For further details of the multi-
ple protein analysis of dichotomized NAB, see Table 4.
DISCUSSION
In this study, we investigated blood proteins shown
in the literature to be associated with A burden in
the brain, using serum samples from AIBL. No pro-
teins were found to pass multiple testing corrections
in a discovery analysis so we implemented a candidate
based approach.
Two candidate proteins (PPY and IgM) showed
association with NAB in the single protein analysis of
the AIBL serum SOMAscan dataset. Both had already
been identified as significant in the AIBL plasma RBM
MAP dataset by Burnham et al. [17].
PPY passed multiple testing corrections for single
protein analysis in all samples for the dichotomized
endpoint. This provides further evidence for claims
made by Chiam et al. who found PPY to be the
most replicated blood protein marker of AD [34].
The direction of association (positive) matched that
of Burnham et al. [17], providing some evidence for
concordance of the SOMAscan platform with RBM
MAP for this protein despite technical differences.
This is also consistent with Sattlecker et al. who used
SOMAscan to show that plasma PPY levels increase
with disease progression in subjects from the combined
AddNeuroMed, Alzheimer’s Research UK/Maudsley
BRC Dementia Case Registry research cohorts [18].
However, the estimate was in the opposite direction to
that described by Kiddle et al. [16]. This could sug-
gest a complex relationship of PPY with NAB that
we may be unable to describe fully with the statistical
approaches applied here. Alternatively, the variation
in direction could be due to lower statistical power
in Kiddle et al. (n = 71) or cohort differences, per-
haps differences between Americans and Australians
or disease stage. Indeed, Lunnon et al. have previ-
ously shown that disease associated markers, albeit
gene expression markers, can frequently change direc-
tion of effect depending on disease stage [35]. The
subjects used by Kiddle et al. from ADNI were at a
much later disease stage (with only three controls) than
the subjects used here.
Doecke et al. have previously shown PPY to be
associated with AD diagnosis in the AIBL cohort
[36]. Similarly, PPY was found to be associated
with diagnosis in ADNI and the Texas Alzheimer’s
Research Consortium [37, 38]. However, there has
been discussion around whether this effect could be
a pharmacological response to the use of acetyl-
cholinesterase inhibitors. Unfortunately, we were
unable to examine this in the AIBL cohort but the
possibility of medication confounding should be inves-
tigated in further studies. Chiam et al. use data from
the AddNeuroMed study to suggest the effect of acetyl-
cholinesterase inhibitor use is not significant on PPY
(Chiam et al., unpublished results).
Additionally, IgM was seen to replicate at the sin-
gle protein level in control samples only. IgM is an
antibody produced by B-cells that appears early in
the course of an infection. This pathway of immune
response has been linked to AD in previous studies
[35]. Furthermore, IgM has been associated with dia-
betes [39]. When a presence of diabetes flag is included
in the IgM model it is not significant. Additionally,
the p-value of IgM remains nominally significant at
0.027 indicating that it is unlikely that this significant
association is a result of disease confounding.
There were 29 candidates that gave non-significant
results. These were: C3, APOE, Fibrinogen, Hap-
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toglobin, Albumin, 1-antitrypsin, 2-macroglobin,
APOA1, C4, Chemokine Ligand 13, Clusterin,
Factor B, Factor H, Gelsolin, Hemopexin, HRG, IgG,
IL13, IL17, IL3, Leptin, MIP1, MMP9, Plasminogen,
Transferrin, SAP, VCAM1, vWF, and APP.
Some of these proteins showed significant q-values
for model statistics (such as R2 and accuracy based on
permutation testing) although they were not significant
in the parametric model. This indicates that greater
sample size is needed for future studies of this nature
in order to reduce the variation of statistics such as R2
and hence give a more reliable estimate.
Multiple protein models constructed in this study
gave mixed success in explaining variation in brain A
burden. Although some provided increased accuracy
or R2 over models of age and APOE 4 number alone,
thedifferenceswereminimalandlargelynogreater than
those provided by some single protein models. LMG
variable importance scores from linear regression mod-
elsalsoemphasized that ageandAPOE4numberwere
the most important variables. Consequently, given a
larger samplesize, ananalysis stratifiedbyAPOEgeno-
typecouldbeused to revealmorecomplex relationships
between APOE and protein markers.
The four studies that contributed candidates for this
analysis used blood plasma samples. However, due to
sample availability, we performed SOMAscan anal-
ysis on blood serum samples. It is possible that this
tissue difference is responsible for the non-replication
of some of the candidates; however, there are studies
suggesting analyte specific consistency across sam-
ple type. O’Bryant et al. show that some blood-based
markers of AD, including pancreatic polypeptide, are
consistent between plasma and serum [38]. Further-
more, our comparison of ranked lists of proteins
associated with age between blood serum (AIBL) and
plasma (Twins UK) showed a high level of concor-
dance on the SOMAscan platform.
Differences between the proteomic approaches used
here (SOMAscan) and in the literature (Myriad RBM,
2DGE, and mass spectrometry) could be driving the
disparity in results between these studies. We see non-
significant p-values for similarity when comparing
ranked lists of proteins associated with age and gender
between SOMAscan and RBM MAP. Due to the simi-
larity in signal between the Twins UK plasma samples
and AIBL serum samples (detailed above), this dif-
ference is likely platform-driven. While SOMAscan
measures the availability of a 3D shape and charge
epitope, mass spectrometry measures mass to charge
ratio. RBM MAP uses antibodies that could be measur-
ing alternative versions or conformations of proteins to
those measured by SOMAscan. It is likely the SOMAs-
can platform would show the highest correlation with
other immunoassays. This is consistent with the obser-
vation that we see the most agreement between AIBL
plasma RBM MAP candidates and our findings here
using serum SOMAscan (PPY and IgM). A study
examining the similarities and differences observed
when running samples across these platforms would
be useful when interpreting results such as these.
Theprimaryanalysisusedinthisstudyfollowsapara-
metric, linear approach following that of three out of
the four studies cited. Burnham et al. used a non-linear,
non-parametric analysis. We investigated the potential
ability to detect interactions and non-linear relation-
ships, and consequently improve model performance,
by building SVM models. These non-parametric mod-
els found slightly improved results suggesting that
non-linearity and interactions could be important in the
relationship between blood proteomics and NAB and
should be considered in further studies.
Throughout the analysis presented here we included
APOE 4 number (0, 1, 2) as a covariate. We did not
include the APOE genotype itself due to small num-
bers of samples in the 24 and 44 groups. We
investigated whether grouping subjects with an 24
genotype with subjects with an 34 genotype was
appropriate given that the 2 allele has been found to be
protective and consequently subjects of the two geno-
types could behave differently. Exploratory analysis
of the PPY and IgM results suggest that the general
trend between the 34 and 24 groups is similar and
consequently it is reasonable to combine them in our
analysis. Supplementary Figures 2 and 3 illustrate this.
It is clear that the sample size used in our analy-
sis limits the power of any conclusions. An additional
factor limiting interpretation of these findings is how
representative the cohort used here is compared to
potential clinical trial recruitment populations, both in
terms of diagnostic groups and prevalence of high A
burden. Differences in prevalence between this cohort
and the target populations can lead to inflated esti-
mates of positive predictive value, the proportion of
test positives that are true positives [40]. This should
be addressed in further work through study of larger
and more representative cohorts.
A known disadvantage of stepwise regression anal-
ysis is a tendency to over fit to the training data. Several
of the multiple protein models created failed to outper-
form age and APOE 4 number in test data which could
be a suggestion that the stepwise models are over fit-
ting to the training data. Alternatively, this may provide
evidence that the candidates considered here provide
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minimal predictive information on NAB, above that
of age and APOE 4 load, when measured in serum
samples using SOMAscan. Studies of larger cohorts
will allow this to be investigated further.
It is promising that we show for the first time
that IgM predicts NAB in asymptomatic individu-
als. However, we note that the majority of candidates
investigated in this study had been selected from pop-
ulations with a variety of diagnoses. Thus, the lack of
significance of association with NAB for most candi-
dates in asymptomatic subjects was not unexpected.
In further work it would be interesting to perform
a discovery analysis on control subjects alone and
identify proteins that are found to link with A bur-
den pre-symptomatically. The proteins identified by
Thambisetty et al. are from a control population but of
small sample size (n = 57) [15].
We were surprised to detect a signal for fibrino-
gen from the SOMAscan technology. Currently it is
thought that there should be no fibrinogen present in
blood serum samples. This may reflect issues of speci-
ficity with the fibrinogen SOMAmer or the presence
of low concentrations of fibrinogen in serum sam-
ples beneath detection thresholds of other assays. We
note that this has been reported before in a study of
tuberculosis [41]. As SOMAscan is a relatively novel
protein quantification technology, more work is needed
to qualify how it compares with other platforms and to
identify the binding sites of SOMAmers.
There is a clear link between the development of
A plaques in the brain and AD but this relation-
ship is not exclusive. That is to say, it is not always
the case that high NAB indicates AD or vice versa;
there are examples of elderly subjects with high A
burden and no cognitive impairment [42]. While this
could be explained by misdiagnosis and A starting a
slow AD process in motion, the alternative hypothesis
would be that A is not causally related to late onset
AD. However, while the focus of AD clinical trials
is predominately anti-A, it is logical to find mark-
ers relevant to those trials. Furthermore, A burden is
appearing in new diagnostic criteria for AD [43]. More
work is needed to thoroughly understand the role of
brain A burden in AD to validate the use mechanistic
action of A, it would be interesting to study a cohort
of subjects with A positivity of a model of A burden
as a diagnostic biomarker. To investigate the prior to
the development of MCI or AD. Unfortunately, the cur-
rent study did not have a sufficient number of samples
(n = 5) meeting this criterion to perform such analysis.
The need for cohorts of this type is clear in order to
advance understanding of the clinical relevance of A.
If the model statistics achieved in this study
are shown to be robust across relevant, larger, and
independent populations, these models could be ben-
eficial in acting as a cost-effective enrichment filter
between the general population and those predicted to
have high NAB. Using a relevant simple blood test as
a pre-screening tool could reduce the PET and CSF
screening failure rate and hence the cost of trials.
CONCLUSIONS
In this study we investigated blood proteins pre-
viously found to be associated with A burden in
the brain using serum samples from AIBL and the
SOMAscan proteomics technology. Two candidate
proteins (PPY and IgM) showed association with NAB
in the AIBL serum SOMAlogic dataset. Notably, IgM
was found to associate with continuous NAB across
control subjects, suggesting it may have utility for pre-
dicting A-positive asymptomatic individuals. There
are several reasons for a lack of significance for the
other candidates including platform differences and the
use of serum rather than plasma samples. To investigate
the possibility of technical differences causing lack of
further replication, further studies are required.
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